Mounjaro, Zepbound shortage eases
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
The US Food and Drug Administration confirmed Thursday that Eli Lilly (LLY) has increased production of its blockbuster ...
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...